Comparing the prognostic impacts of angiogenesis, lymphangiogenesis and lymphatic invasion (LI) in small cell lung carcinomas (SCLC) Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011
Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006
Prognostic value of non-angiogenic and angiogenic growth patterns in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 40s Year: 2004
Comparing LYVE-1 and D2-40 expression in small cell lung carcinomas (SCLC); association with clinical parameters and lymphatic invasion Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011
Vascular endothelial growth factor (VEGF) expression in non small cell lung cancer and its association with histopathologic type, stage, lymphnode involvement, recurrence and distant metastasis Source: Eur Respir J 2003; 22: Suppl. 45, 393s Year: 2003
Vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt-1, VEGF-R2-KDR/Flk-1) as prognostic indicators in small cell lung carcinomas (SCLC) Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement Source: Eur Respir J 2007; 30: 21-26 Year: 2007
Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015
Prognostic impact of lymphangiogenesis and lymphatic invasion (CD105 expression) in small cell lung carcinomas Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015
LSC Abstract – Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features Source: International Congress 2016 – Lung cancer immunology: latest research Year: 2016
Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm Source: Eur Respir J 2010; 36: 1355-1361 Year: 2010
How to treat a T1-T3N0 non-small cell lung cancer (NSCLC) with isolated brain metastasis Source: International Congress 2015 – How to treat brain metastases Year: 2015
The prognostic influence of tumor infiltrating M1 and M2 phenotype macrophages in resected non-small cell lung cancer Source: International Congress 2016 – Lung cancer immunology: latest research Year: 2016
Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019